Alzheimer's Disease Clinical Trial
— LOCUSOfficial title:
Focus on the Locus Coeruleus Network With 7 T MRI: Link to Memory (Dys)Function
The cause of Alzheimer's disease, the most common form of dementia, remains unknown.
Neuropathological studies suggest that a small area in the brainstem, the locus coeruleus,
might be the site of the onset of the disease. This area is the sole source of noradrenalin
to the brain, a neurotransmitter involved in arousal, but also cognitive functions. Animal
and pharmacological studies have hinted towards an important role of this area in memory
functioning. However, these studies were hampered by the limited spatial resolution, making
it hard to clearly localize the locus coeruleus in the brain. New developments in brain
imaging allow now to visualize the brain with stunning precision. Furthermore, a non-invasive
new stimulation method, transcutaneous vagus nerve stimulation, is believed to excite the
locus coeruleus and thereby influencing neuronal networks and memory functioning.
There are three aims in this project:
1. To investigate how the functional interaction between the locus coeruleus and other
brain areas, in particular the medial temporal lobe areas, during memory processes
(encoding, consolidation and retrieval) change with development of Alzheimer's disease.
2. To investigate associations between noradrenaline, memory performance and brain
functioning. The investigators aim to investigate how acute noradrenalin levels change
during the different memory processes and whether or not this is beneficial for
performance. Furthermore, the investigators will investigate whether this interaction
between noradrenalin, memory performance and brain functioning is different healthy
older individuals (n =35) or patients with prodromal Alzheimer's disease (n =35).
3. To investigate the underlying neural network changes during transcutaneous vagus nerve
stimulation. The investigators will focus on differences in functional connectivity
between the locus coeruleus and the medial temporal lobe areas in healthy older
individuals and prodromal Alzheimer's disease patients. An experimental condition will
be compared with a sham condition in a pseudo-randomized cross-over design.
Status | Recruiting |
Enrollment | 70 |
Est. completion date | December 2020 |
Est. primary completion date | December 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 85 Years |
Eligibility |
Inclusion Criteria: For the patients: - diagnosis of prodromal Alzheimer's disease based on the latest research criteria (clinical assessment at the memory clinic : presence of at least a memory impairment, memory complaints expressed by the patient or informant, no problems in daily life functioning, no dementia and presence of biomarkers - Clinical Dementia Rating score of 0.5 ( - Mini-Mental State Examination (MMSE) = 23 and being mentally competent (in general, individuals with a MMSE = 18 are considered mentally competent) - Age: between 60 and 85 years old - 50% female - Right-handedness - Average level of education - Informed consent before participation in the study For the healthy older individuals: - Average neuropsychological test results, in accordance with normative data, corrected for age, education and gender - No substantial memory complaints (according to the participant) - Age: between 60 and 85 years old - 50% female - Right-handedness - Average level of education - Informed consent before participation in the study Exclusion Criteria: - Reduced vision - Psychoactive medication use - Abuse of alcohol and drugs - Cognitive impairment due to alcohol/drug abuse or abuse of other substances - Past or present psychiatric or neurological disorders (major depression, schizophrenia, bipolar disorder, psychotic disorder (or treatment for it), epilepsy, stroke, Parkinson's disease, multiple sclerosis, brain surgery, brain trauma, electroshock therapy, kidney dialysis, Menière's disease, brain infections) - Major vascular disorders (e.g. stroke) - Heart diseases or pacemakers - Contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, body tattoos) |
Country | Name | City | State |
---|---|---|---|
Netherlands | Maastricht University | Maastricht |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center | Netherlands Organisation for Scientific Research |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Basic descriptives | gender, date of birth, socio-economic status, educational level, medical history, medication use: will be used descriptively | 15 minutes | |
Other | Vascular measurements | Mean arterial blood pressure, cardiovascular risk factors and vascular pathology will be assessed descriptively and could also lead to exclusion of participants. | 15 min | |
Other | Alpha-peak frequency | the individual mean alpha-peak frequency will be assessed with rest EEG to determine stimulation parameters. | 30 minutes | |
Other | Side effects | via a questionnaire we will collect the level of side effects after stimulation (scale 1-5) | 10 min | |
Other | Blood pressure and heart rate | Blood pressure and heart rate will be measured before and after the sessions (seated and standing) in order to monitor response to the stimulation. | 20 minutes | |
Primary | Blood Oxygen Level Dependent (BOLD) response during a memory task | BOLD response contrasts during encoding and retrieval. For encoding: comparing neutral versus emotional, comparing old versus prodromal AD and the interaction emotional level by group. For retrieval: correctly remembered versus those incorrectly remembered; neutral versus emotional faces; lures, mistakes and hits. These contrasts will be investigated comparing both groups. BOLD responses during the memory task will also be compared across sessions (sham versus stimulation) for both groups. Consolidation: task-free, so the BOLD response in the locus coeruleus will be correlated with the BOLD response in any other voxel of the grey matter of the brain over time (seed-based resting-state analyses). |
60 minutes | |
Primary | Performance on the memory task | Mean reaction times and accuracy levels during encoding and retrieval for emotional and neutral face-name associations and for old and prodromal AD patients. Mean reaction times and accuracy levels will also be compared across sessions: sham versus stimulation for both groups Mean reaction times and accuracy levels will also be correlated with BOLD responses during the memory task. |
60 minutes | |
Primary | Noradrenalin levels during the memory task | Noradrenalin levels will be measured 7 times: double baseline, before encoding, after encoding, before retrieval, after retrieval and follow-up. Noradrenalin levels will be correlated with BOLD responses during the memory task. |
60 minutes | |
Secondary | Grey matter volume of the locus coeruleus | manual measurement of the number of voxels of the locus coeruleus: to compare groups | 5 mintues | |
Secondary | shape properties of the locus coeruleus | Correspondence of the location between triangle meshes (shape of the locus coeruleus) will be compared between groups | 5 minutes | |
Secondary | Performance on neuropsychological tests | Total score on the mini-mental state examination, fluency test, letter-digit-substitution test, concept shifting task, stroop color word test and the word learning task will be compared across groups. For the stroop color word task and the concept shifting task we will also compare reaction times between both groups. These scores will be correlated to the grey matter volume of the locus coeruleus and the shape properties of the locus coeruleus. |
30 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT01922258 -
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
|
Phase 3 |